Integra LifeSciences (IART) stock price, revenue, and financials

Integra LifeSciences market cap is $5.7 b, and annual revenue was $1.37 b in FY 2020

$5.7 B

IART Mkt cap, 15-Oct-2021

$390 M

Integra LifeSciences Revenue Q2, 2021
Integra LifeSciences Gross profit (Q2, 2021)238.7 M
Integra LifeSciences Gross profit margin (Q2, 2021), %61.2%
Integra LifeSciences Net income (Q2, 2021)35.1 M
Integra LifeSciences EBIT (Q2, 2021)51.9 M
Integra LifeSciences Cash, 30-Jun-2021397.4 M
Integra LifeSciences EV6.2 B
Get notified regarding key financial metrics and revenue changes at Integra LifeSciencesLearn more
Banner background

Integra LifeSciences Revenue

Integra LifeSciences revenue was $1.37 b in FY, 2020

Embed Graph

Integra LifeSciences Revenue Breakdown

Embed Graph

Integra LifeSciences revenue breakdown by business segment: 34.4% from Orthopedics and Tissue Technologies and 65.6% from Codman Specialty Surgical

Integra LifeSciences revenue breakdown by geographic segment: 5.6% from Rest of World, 10.4% from Asia Pacific, 13.0% from Europe and 71.0% from United States

Integra LifeSciences Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.2b1.5b1.5b1.4b

Revenue growth, %

24%3%

Cost of goods sold

435.5m571.5m564.7m520.8m

Gross profit

752.7m900.9m952.9m851.0m

Gross profit Margin, %

63%61%63%62%

R&D expense

63.5m78.0m79.6m77.4m

General and administrative expense

624.1m690.7m687.6m594.5m

Operating expense total

707.9m789.9m859.1m699.7m

Depreciation and amortization

20.4m21.2m27.0m27.8m

EBIT

44.8m111.0m93.8m151.4m

EBIT margin, %

4%8%6%11%

Interest expense

35.0m64.7m54.0m

Interest income

255.0k2.8m10.8m9.3m

Pre tax profit

11.4m57.4m60.1m93.5m

Income tax expense

(53.4m)(3.4m)9.9m(40.4m)

Net Income

64.7m60.8m50.2m133.9m

EPS

0.80.70.6

Integra LifeSciences Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

174.9m138.8m198.9m470.2m

Accounts Receivable

251.8m265.7m275.3m225.5m

Prepaid Expenses

99.1m90.2m67.9m69.3m

Inventories

296.3m280.3m316.1m310.1m

Current Assets

822.1m775.1m858.2m1.2b

PP&E

269.3m300.1m337.4m287.5m

Goodwill

937.9m926.5m954.3m932.4m

Total Assets

3.2b3.1b3.3b3.6b

Accounts Payable

94.0m76.1m113.1m54.6m

Short-term debt

60.0m22.5m57.3m91.6m

Current Liabilities

348.9m262.6m331.3m401.0m

Long-term debt

1.8b1.3b1.4b563.0m

Total Debt

1.8b1.4b1.5b654.5m

Total Liabilities

2.2b1.7b1.9b2.1b

Common Stock

813.0k880.0k887.0k893.0k

Preferred Stock

Additional Paid-in Capital

821.8m1.2b1.2b1.3b

Retained Earnings

285.2m348.4m398.6m532.3m

Total Equity

962.3m1.4b1.4b1.5b

Debt to Equity Ratio

1.9 x1 x1 x

Debt to Assets Ratio

0.6 x0.4 x0.4 x

Financial Leverage

3.3 x2.3 x2.3 x2.4 x

Quarterly

USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

189.4m183.8m206.0m157.0m176.1m208.0m357.7m361.0m396.3m409.0m397.4m

Accounts Receivable

272.3m258.4m248.7m279.1m296.5m281.1m245.5m179.1m218.2m223.5m229.8m

Prepaid Expenses

96.5m88.7m82.4m99.6m99.6m92.1m67.3m67.3m69.8m78.5m81.5m

Inventories

290.5m290.5m290.8m287.0m296.5m302.6m338.1m358.8m307.8m328.0m323.6m

Current Assets

848.7m821.3m828.0m822.7m868.7m883.8m1.0b966.2m1.2b1.0b1.0b

PP&E

274.0m277.0m287.0m306.4m316.4m319.4m335.9m334.3m294.4m296.2m295.8m

Goodwill

944.5m927.1m926.4m922.5m926.7m945.3m951.6m956.2m919.6m1.0b1.0b

Total Assets

3.2b3.2b3.2b3.2b3.3b3.3b3.4b3.4b3.5b3.7b3.7b

Accounts Payable

87.0m84.0m86.4m100.6m107.2m94.2m97.1m58.3m50.3m61.5m65.5m

Short-term debt

60.0m11.3m33.8m58.4m56.8m13.0m24.4m35.0m58.9m45.0m

Current Liabilities

336.0m233.3m258.3m288.1m315.1m302.6m246.5m212.4m255.1m412.3m318.8m

Long-term debt

1.8b1.5b1.4b1.3b1.4b1.5b1.7b1.6b1.6b657.8m866.3m

Total Debt

1.8b1.5b1.4b1.4b1.5b1.5b1.7b1.7b1.6b716.7m911.3m

Total Liabilities

2.2b1.8b1.8b1.8b1.9b2.0b2.1b2.0b2.1b2.2b2.1b

Common Stock

817.0k877.0k880.0k882.0k883.0k886.0k889.0k892.0k892.0k894.0k895.0k

Preferred Stock

Additional Paid-in Capital

822.5m1.2b1.2b1.2b1.2b1.2b1.2b1.3b1.3b1.2b1.2b

Retained Earnings

297.5m309.9m323.2m381.1m410.9m383.3m407.6m407.2m439.5m574.9m610.0m

Total Equity

998.4m1.3b1.4b1.4b1.4b1.4b1.3b1.3b1.4b1.5b1.6b

Debt to Equity Ratio

1.8 x1.1 x1 x1 x1 x1.1 x1.3 x1.2 x1.2 x

Debt to Assets Ratio

0.6 x0.5 x0.5 x0.4 x0.4 x0.5 x0.5 x0.5 x0.5 x

Financial Leverage

3.3 x2.4 x2.3 x2.3 x2.3 x2.4 x2.6 x2.5 x2.5 x2.4 x2.4 x

Integra LifeSciences Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

64.7m60.8m50.2m133.9m

Depreciation and Amortization

88.9m110.7m109.5m116.0m

Accounts Receivable

(89.7m)(17.0m)(9.4m)52.1m

Inventories

99.0k8.3m(43.3m)(48.3m)

Accounts Payable

95.3m3.6m14.7m(57.5m)

Cash From Operating Activities

114.5m199.7m231.4m203.8m

Purchases of PP&E

(43.5m)(77.7m)(69.5m)(38.9m)

Cash From Investing Activities

(1.2b)(49.7m)(162.7m)(68.1m)

Long-term Borrowings

(117.0m)(660.0m)(246.1m)(441.0m)

Cash From Financing Activities

1.2b(180.9m)(8.8m)121.6m

Net Change in Cash

72.9m(36.1m)60.1m271.3m

Integra LifeSciences Ratios

USDFY, 2017

Revenue/Employee

270.1k

Debt/Equity

1.9 x

Debt/Assets

0.6 x

Financial Leverage

3.3 x

Integra LifeSciences Employee Rating

3.3491 votes
Culture & Values
2.9
Work/Life Balance
3.3
Senior Management
2.6
Salary & Benefits
3
Career Opportunities
2.6
Source